Keio Innovation Initiative has made an additional investment in Cellusion, a venture company utilizing research results from Keio University and other institutions. Through this capital increase, Cellusion will raise a total of 1.1 billion yen to prepare for domestic and overseas clinical trials of its lead program, iPS cell-derived corneal endothelial replacement cells (CLS001), to strengthen its research and organizational structure, and to advance research and development for subsequent pipeline products.

For more details, please see the press release.